Trading in Novo Nordisk shares by board members, executives and associated persons

    Trading in Novo Nordisk shares by board members, executives and associated persons  

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated

a)Name of the Board member/Executive/Associated PersonNovo Holdings A/S, associated to Kasim Kutay2 Reason for the notification

a)Position/statusMember of the Board of Directorsb)Initial notification/AmendmentInitial notification3 Details of the issuer

a)NameNovo Nordisk A&Sb)LEI549300DAQ1CVT6CXN3424 Details of the transaction(s)

a)Description of the financial instrument, type of instrument, Identification codeShares

Novo Nordisk B DK0062498333b)Nature of the transactionSale of sharesc)Price(s) and volume(s)

Price(s)	Volume(s)
DKK 860.02	6,311,250 shares

d)Aggregated information

• Aggregated volume
• Price

6,311,250 sharesDKK 5,427,801,225.00e)Date of the transaction2024-05-06f)Place of the transactionOutside a trading venue

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 [e-mail]	Liz Skrbkova (US)+1 609 917 [e-mail]
Investors:
Daniel Muusmann Bohsen[phone] [e-mail]	Jacob Martin Wiborg Rode+45 3075 [e-mail]
David Heiberg Landsted [phone] [e-mail]	Mark Joseph Root (US) +1 848 213 [e-mail]
Sina Meyer [phone] [e-mail]	Frederik Taylor Pitter [phone] [e-mail]
Ida Melvold Gjøsund [phone] [e-mail]

Company announcement No 39 / 2024

Attachment

• CA24050_insider trading